News Briefing channel feed

Roche's Alzheimer's drug spurred bio­mark­er changes but no cog­ni­tive im­pact — pa­per; vTv out-li­cens­es for­mer lead pro­gram

4 years ago

As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin patent bid

4 years ago

Jim Green­wood opens new pol­i­cy shop, with an eye on drug price con­trols; Mod­er­na, CRISPR, Mus­tang re­ceive tax breaks in Mass­a­chu­setts

4 years ago

Don’t hold your breath wait­ing for FDA nom­i­nee; A pri­or­i­ty re­view for an­oth­er Bris­tol My­ers part­ner

4 years ago

No­vo Nordisk to re­search oral obe­si­ty treat­ment; Dana-Far­ber taps in­to Har­bour Bio­Med's mice plat­form in mul­ti­year deal

4 years ago

Is­rael's VBL Ther­a­peu­tics hit with CMC de­lays in ovar­i­an can­cer study; No­vo Hold­ings buys out di­ag­nos­tics play­er BBI

4 years ago

FDA push­es back As­cendis' PDU­FA for long-act­ing hor­mone ther­a­py; De­bio­pharm takes home a win in mid-stage test for ADC

4 years ago

Au­to­lus claims a CAR-T win at EHA; Ima­go touts two PhII tri­al wins for rare dis­ease drug

4 years ago

Verona signs Chi­na deal for PhI­II COPD drug; Te­va con­tin­ues le­gal bat­tle with Eli Lil­ly, al­leg­ing new patent in­fringe­ments on mi­graine drug

4 years ago

Em­ploy­ees in Flori­da IBS tri­al plead guilty for fal­si­fy­ing med­ical records; Cys­tic fi­bro­sis tablet Trikaf­ta now avail­able for chil­dren 6 and old­er

4 years ago

In­cyte faces de­lay on FDA's Jakafi de­ci­sion for cGVHD; Bay­er's Parkin­son's cell ther­a­py en­ters the clin­ic

4 years ago

Spring­Works and Seagen team up in mul­ti­ple myelo­ma; Mer­ck and Ei­sai build out Keytru­da/Lenvi­ma da­ta

4 years ago

Fate sees pos­i­tive B-cell lym­phoma da­ta at #AS­CO21; Imag­inAb se­cures fund­ing for CD8 imag­ing tri­als

4 years ago

Mer­ck­'s wom­en's health spin­off goes pub­lic in NYSE de­but; A Hous­ton an­ti­body play­er scores fresh funds to chase tu­mors

4 years ago

Cell­tri­on's rheuma­toid arthri­tis drug meets both end­points in PhI­II; New com­pa­ny Tri­bune emerges to take on fi­brot­ic dis­eases

4 years ago

Broad In­sti­tute's Er­ic Lan­der con­firmed to Biden cab­i­net; Leg­end re­veals the BC­MA CAR-T da­ta pack­age be­hind pri­or­i­ty re­view

4 years ago

Chi­na's patent law re­vi­sions set to take ef­fect June 1; Ver­ri­ca's sec­ond trip to the FDA is de­layed

4 years ago

Astel­las out­lines an­oth­er five-year plan; Bay­er's VC arm leaps in­to dig­i­tal health

4 years ago

PureTech's video game for AD­HD gets big Se­ries D fi­nanc­ing; Day One in­creas­es term sheet ahead of ex­pect­ed IPO

4 years ago

New da­ta point to how Keytru­da changed lung can­cer treat­ment; A Hous­ton biotech earns ear­ly back­ers in quest to turn 'cold' tu­mors 'hot'

4 years ago

Ve­rastem wins break­through nod for com­bo ther­a­py in ovar­i­an can­cer; EMA picks up speedy re­view of Bio­Mar­in's gene ther­a­py

4 years ago

An­no­vis Bio claims wins in Alzheimer's and Parkin­son's, shares sky­rock­et; FDA de­lays de­ci­sion for Omeros' nar­so­plimab

4 years ago

Bio­Th­eryX col­lects $92M in Se­ries E round; WuXi Bi­o­log­ics ups its stake in an emerg­ing ADC play­er

4 years ago

Idera of­fi­cial­ly puts to rest its Phase III tri­al in ad­vanced melanoma; BeiGene nabs pri­or­i­ty re­view for sN­DA

4 years ago
First page Previous page 29303132333435 Next page Last page
A service from the Financial Times